Slingshot members are tracking this event:
Agios Pharma (AGIO) to complete Phase 1/2 Study of AG-221 in Subjects with Hematologic Malignancies with an IDH2 Mutation in September 2017
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Jun 24, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 1/2 Study, Ag-221, Hematologic Malignancies, Idh2 Mutation, Open Label